Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).

Trial Details

NCT ID
NCT06482801
Phase
PHASE2
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Cytohistological confirmation is required for diagnosis of cancer.
  • Signed informed consent before recruiting.
  • Age above 18 years with estimated survival over 3 months.
  • Child-Pugh class A or B/Child score \> 7; ECOG score \< 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →